bivalent mrna booster vaccine Search Results


mrna booster vaccine  (BioNTech)
90
BioNTech mrna booster vaccine
Mrna Booster Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mrna booster vaccine/product/BioNTech
Average 90 stars, based on 1 article reviews
mrna booster vaccine - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
bivalent mrna covid-19 booster vaccine (ancestral + ba.4/5 voc)  (BioNTech)
90
BioNTech bivalent mrna covid-19 booster vaccine (ancestral + ba.4/5 voc)
Bivalent Mrna Covid 19 Booster Vaccine (Ancestral + Ba.4/5 Voc), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bivalent mrna covid-19 booster vaccine (ancestral + ba.4/5 voc)/product/BioNTech
Average 90 stars, based on 1 article reviews
bivalent mrna covid-19 booster vaccine (ancestral + ba.4/5 voc) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
bivalent covid-19 mrna vaccine boosters  (Moderna)
90
Moderna bivalent covid-19 mrna vaccine boosters
Bivalent Covid 19 Mrna Vaccine Boosters, supplied by Moderna, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bivalent covid-19 mrna vaccine boosters/product/Moderna
Average 90 stars, based on 1 article reviews
bivalent covid-19 mrna vaccine boosters - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mrna-based bivalent ba.1 booster vaccine  (BioNTech)
90
BioNTech mrna-based bivalent ba.1 booster vaccine
Mrna Based Bivalent Ba.1 Booster Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mrna-based bivalent ba.1 booster vaccine/product/BioNTech
Average 90 stars, based on 1 article reviews
mrna-based bivalent ba.1 booster vaccine - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
bivalent covid-19 mrna booster vaccination  (Pfizer Inc)
90
Pfizer Inc bivalent covid-19 mrna booster vaccination
Bivalent Covid 19 Mrna Booster Vaccination, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bivalent covid-19 mrna booster vaccination/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
bivalent covid-19 mrna booster vaccination - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
bivalent vaccine boosters containing ancestral well ba.5 spike mrna  (Moderna)
90
Moderna bivalent vaccine boosters containing ancestral well ba.5 spike mrna
Bivalent Vaccine Boosters Containing Ancestral Well Ba.5 Spike Mrna, supplied by Moderna, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bivalent vaccine boosters containing ancestral well ba.5 spike mrna/product/Moderna
Average 90 stars, based on 1 article reviews
bivalent vaccine boosters containing ancestral well ba.5 spike mrna - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ba4/5 bivalent mrna booster vaccines  (Urschel Laboratories)
90
Urschel Laboratories ba4/5 bivalent mrna booster vaccines
Ba4/5 Bivalent Mrna Booster Vaccines, supplied by Urschel Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ba4/5 bivalent mrna booster vaccines/product/Urschel Laboratories
Average 90 stars, based on 1 article reviews
ba4/5 bivalent mrna booster vaccines - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
bivalent omicron adapted mrna booster vaccine  (BioNTech)
90
BioNTech bivalent omicron adapted mrna booster vaccine
Overview of study design. The main risk period was days 0-28 after receipt of <t>a</t> <t>bivalent</t> covid-19 <t>mRNA</t> booster as fourth dose. The total reference period consisted of ≥29 days after a third dose (up to the day before the fourth dose (ie, day 0 minus 1 day)) and the fourth dose (second booster). See supplementary figure S1 for the distribution of reference period and main risk period person time during the study period
Bivalent Omicron Adapted Mrna Booster Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bivalent omicron adapted mrna booster vaccine/product/BioNTech
Average 90 stars, based on 1 article reviews
bivalent omicron adapted mrna booster vaccine - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pfizer/biontech bivalent covid-19 mrna vaccine boosters  (BioNTech)
90
BioNTech pfizer/biontech bivalent covid-19 mrna vaccine boosters
Overview of study design. The main risk period was days 0-28 after receipt of <t>a</t> <t>bivalent</t> covid-19 <t>mRNA</t> booster as fourth dose. The total reference period consisted of ≥29 days after a third dose (up to the day before the fourth dose (ie, day 0 minus 1 day)) and the fourth dose (second booster). See supplementary figure S1 for the distribution of reference period and main risk period person time during the study period
Pfizer/Biontech Bivalent Covid 19 Mrna Vaccine Boosters, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pfizer/biontech bivalent covid-19 mrna vaccine boosters/product/BioNTech
Average 90 stars, based on 1 article reviews
pfizer/biontech bivalent covid-19 mrna vaccine boosters - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Overview of study design. The main risk period was days 0-28 after receipt of a bivalent covid-19 mRNA booster as fourth dose. The total reference period consisted of ≥29 days after a third dose (up to the day before the fourth dose (ie, day 0 minus 1 day)) and the fourth dose (second booster). See supplementary figure S1 for the distribution of reference period and main risk period person time during the study period

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Overview of study design. The main risk period was days 0-28 after receipt of a bivalent covid-19 mRNA booster as fourth dose. The total reference period consisted of ≥29 days after a third dose (up to the day before the fourth dose (ie, day 0 minus 1 day)) and the fourth dose (second booster). See supplementary figure S1 for the distribution of reference period and main risk period person time during the study period

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Characteristics of study participants vaccinated with a monovalent mRNA vaccine as a third dose and a bivalent omicron adapted vaccine as a fourth dose in Denmark. Values are number (percentage) unless stated otherwise

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Characteristics of study participants vaccinated with a monovalent mRNA vaccine as a third dose and a bivalent omicron adapted vaccine as a fourth dose in Denmark. Values are number (percentage) unless stated otherwise

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques: Western Blot, Northern Blot

Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by sex. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by sex. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by age subgroups. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by age subgroups. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by type of vaccine received. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. *Corresponding number of events and person years are presented in supplementary table S3. NE=not estimable

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by type of vaccine received. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. *Corresponding number of events and person years are presented in supplementary table S3. NE=not estimable

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Risk of cerebrovascular infarction, myocarditis, and pericarditis after vaccination with a bivalent omicron adapted booster as fourth dose within 28 days in Danish adults aged ≥50 year during 15 September 2022 to 10 December 2022, including by sex, age, and vaccine type

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of cerebrovascular infarction, myocarditis, and pericarditis after vaccination with a bivalent omicron adapted booster as fourth dose within 28 days in Danish adults aged ≥50 year during 15 September 2022 to 10 December 2022, including by sex, age, and vaccine type

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques: